-+ 0.00%
-+ 0.00%
-+ 0.00%

IMUNON Eliminates Headcount Not Essential To Phase 3 Trial

Benzinga·02/05/2026 13:15:44
Listen to the news

Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study

Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the company

Phase 3 Study enrollment remains ahead of schedule and advances the company toward future BLA filing